You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer
|
|---|---|
| Published in |
Journal of Translational Medicine, November 2013
|
| DOI | 10.1186/1479-5876-11-291 |
| Pubmed ID | |
| Authors |
Shingo Asahara, Kazuyoshi Takeda, Kenji Yamao, Hiroyuki Maguchi, Hiroki Yamaue |
| Abstract |
We previously developed an immunotherapy treatment utilizing a cancer vaccine reagent KIF20A-66 in order to treat pancreatic cancer. KIF20A-66 is HLA-A24-restricted epitope peptide derived from KIF20A, a member of kinesin super family protein 20A that is significantly transactivated in pancreatic cancer. In this report, we further demonstrated non-randomized, open-label, single centered phase I/II clinical trial of immunotherapy using the KIF20A-66 peptide for the patients with advanced pancreatic cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 55 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 18% |
| Student > Master | 8 | 15% |
| Researcher | 7 | 13% |
| Student > Doctoral Student | 4 | 7% |
| Student > Bachelor | 3 | 5% |
| Other | 8 | 15% |
| Unknown | 15 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 15% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Agricultural and Biological Sciences | 6 | 11% |
| Immunology and Microbiology | 6 | 11% |
| Business, Management and Accounting | 1 | 2% |
| Other | 8 | 15% |
| Unknown | 19 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 September 2018.
All research outputs
#5,240,751
of 25,374,917 outputs
Outputs from Journal of Translational Medicine
#914
of 4,635 outputs
Outputs of similar age
#42,363
of 207,723 outputs
Outputs of similar age from Journal of Translational Medicine
#9
of 77 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,635 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,723 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.